Company shares last traded at $3.41 which is significantly higher than the 50 day moving average which is $2.64 and which is quite a bit higher than the 200 day moving average of $1.71. The 50 day moving average moved up $0.77 and the 200 day average went up $1.70 or +99.99%. Trading was heavy with 727K shares changing hands in the last trading session. Shares saw a steep increase in trading volume of 625.36% over the normal average daily volume.
Short traders are feeling a little more bearish lately as evidenced by the increase in short interest. The company had a rise in short interest of 0.60% between September 15, 2017 and September 29, 2017. Short shares increased from 764,871 to 769,436 over that period. Days to cover decreased -3.0 to 2.0 and the percentage of shorted shares is 0.12% as of September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (CLSN). Bank Of America Corp /de/ bolstered its holdings by buying 5,946 shares an increase of 243.3%. Bank Of America Corp /de/ claims 8,390 shares with a value of $2,000. The value of the position overall is up by 100.0%. Susquehanna International Group, Llp divested its ownership by selling 543 shares a decrease of 4.9% from 09/30/2016 to 03/31/2017. Susquehanna International Group, Llp currently owns 10,557 shares valued at $3,000. The total value of its holdings decreased 78.6%.
Jane Street Group, LLC expanded its stake by buying 122,931 shares an increase of 667.6% as of 03/31/2017. Jane Street Group, LLC now controls 141,345 shares worth $41,000. The total value of its holdings increased 86.4%. As of the end of the quarter Morgan Stanley had disposed of 29 shares trimming its stake by 0.5%. The value of the investment in CLSN decreased from $2,000 to $2,000 decreasing 0.0% since the last quarter.
On October 5, 2017 the stock rating was rated “Buy” by Maxim Group which is up from the previous “Buy” rating.
In the last earnings report the EPS was $-5.58 and is projected to be $-3.50 for the current year with 8,351,000 shares outstanding. Next quarter’s EPS is expected be $-0.39 with next year’s EPS projected to be $-1.17.
Celsion Corporation (Celsion), launched on May 17, 2000, is an oncology drug development company. The Company is focused on developing a portfolio of cancer treatments, including directed chemotherapies, deoxyribonucleic acid (DNA)-mediated immunotherapy and ribonucleic acid (RNA)-based therapies. Its product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for the treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a DNA mediated immunotherapy for the localized treatment of ovarian and brain cancers. The Company has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer RNA..